On December 11, the Global Health Drug Discovery Institute (GHDDI) proudly announced the official launch of "AI Kongming," China's very own, independently developed AI-driven drug discovery platform. This innovative platform revolutionizes the drug development landscape by enabling intelligent design at every stage of the process. As China's inaugural open AI drug discovery platform, it is specifically designed to confront global health challenges, including malaria, tuberculosis, and viral diseases. Its primary goal is to boost both the efficiency and success rate of drug development, spanning from the initial discovery of drug targets to the selection of clinical candidates. By doing so, it aims to expedite the development of new drugs in crucial areas. To date, the platform has undergone rigorous validation across numerous real-world drug development pipelines, demonstrating substantial enhancements in both the hit rates of candidate molecules and the efficiency of their optimization.